openPR Logo
Press release

Peptide CDMO (Pharmaceutical) Market: Navigating Size Success through 9.3 % CAGR Surge by 2031

06-19-2024 08:14 PM CET | Health & Medicine

Press release from: InsightAce Analytic Pvt. Ltd.

Peptide CDMO (Pharmaceutical) Market: Navigating Size Success

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Peptide CDMO (Pharmaceutical) Market Trends, Industry Competition Analysis, Company Profiles, Revenue Estimates and Forecast To 2031."

According to the latest market research report, The Peptide CDMO (Pharmaceutical) Market Size is valued at 2173.44 Million in 2022 and is predicted to reach 4784.50 Million by the year 2031 at a 9.3 % CAGR during the forecast period for 2023-2031. By region, Asia Pacific dominated the market with a market share of 42.4% in 2021.

Request for Sample Pages: https://www.insightaceanalytic.com/request-sample/1202

Peptides are small protein molecules that contain fewer amino acids compared to proteins. Peptide therapeutics play an essential role in addressing unmet medical needs. Several peptide drugs have reached the market for treating different diseases, including cancer, diabetes, osteoporosis, chronic pain, multiple sclerosis, and HIV infection. Peptide CDMO is considered an emerging market due to its excellent peptide therapeutic properties and promising potential for the contract API manufacturing industry.

Factors such as the developing healthcare infrastructure, increasing medical applications of peptides, rising healthcare expenditures, emerging peptide design technologies, growing usage of peptides for drug development, rising R&D investments for peptide-based therapies, high prevalence of chronic diseases, and the use of bioinformatics and systematic biological approaches for peptide designing are predicted to drive the peptide CDMO (pharmaceutical) market during the forecast years. The high prevalence of chronic and infectious diseases leads to increased drug demands. Hence, pharmaceutical companies began to opt for peptides and CDMOs services to manage the product manufacturing burden. Peptides are used due to their high specificity, tolerability, and ease of manufacturing, and contract manufacturing services save time and enhance production efficiency. Likely to surge the business growth opportunities for the peptide CDMO (pharmaceutical) market over the projected period.

However, factors such as the expensive CDMOs services and the need for specialized expertise for peptide production are estimated to impede the market development over the estimated timeframe.

Request for ToC/Proposal: https://www.insightaceanalytic.com/report/global-peptide-cdmo-pharmaceutical-market-/1202

Regionally, North America, followed by Europe, is projected to lead the peptide CDMO (pharmaceutical) market during the forecast period (2023-2031), owing to the well-developing CDMOs, availability of peptide synthesis technologies, and the surging demand for peptides and drugs to treat chronic conditions.

Key market players operating in the peptide CDMO (pharmaceutical) market include AmbioPharm, Auspep, Bachem, BCN Peptide, CPC Scientific, CBL- Chemical and Biopharmaceutical Laboratories, ScinoPharm, Olon, Belyntic, Ferring Pharma, Numaferm, Hybio Pharmaceutical, Provepharm life solutions, Enzene Biosciences, Ardena Holding, Stelis Biopharma, Piramal Pharma, Space Peptides PharmaceuticalCreative Peptides, CSBio, Corden Pharma, PolyPeptide, Hybio Pharmaceutical, Peptide Institute, Pepscan, Almac, Chinese Peptide, CreoSalus Inc, Vivitide, Senn Chemicals, Wuxi AppTec, among others.

Key developments in the market:
• In January 2022, CordenPharma collaborated with PeptiSystems, a Swedish-based developer of peptide and oligonucleotide therapeutic process development and manufacturing instruments, to reduce the footprint impact and improve the Process Mass Intensity (PMI) of peptide manufacturing processes.
• In December 2021, Pepscan extended its column purification technology with a mid-sized column packer. This technology significantly reduces purification time and provides optimal flexibility when synthesizing peptides.
• In September 2021, CEM Corporation and AmbioPharm, Inc. partnered to produce GMP peptides for the global market. The partnership will involve an exclusive1 use of CEM's large-scale microwave peptide synthesis technology to produce GMP peptides up to multi-kilogram quantities using proprietary scalable reactors. Also, it will enable rapid and efficient production of peptide new chemical entities (NCE's) using the latest technologies available.
• In July 2021, CordenPharma expanded its peptide manufacturing capacity in CordenPharma Colorado, their GMP API facility in Boulder, CO (US). CordenPharma Colorado is the largest worldwide peptide API producer leading the global peptide market.

Obtain Full Report @ https://www.insightaceanalytic.com/enquiry-before-buying/1202

Market Segments
Global Peptide CDMO (Pharmaceutical) Market, by Scale of Operation, 2023-2031 (Value US$ Mn)
• Preclinical / Clinical
• Commercial

Global Peptide CDMO (Pharmaceutical) Market, by Method Used, 2023-2031 (Value US$ Mn)
• Chemical Synthesis Method
• Non-Chemical Synthesis Method

Global Peptide CDMO (Pharmaceutical) Market, by By Applications, 2023-2031 (Value US$ Mn)
• Peptide Supplements
• Peptide Vaccines
• Peptides as Radio-Theranostic Agents
• Cell Penetrating Peptides (CPPs)
• Affinity Ligands
• Protein Mimics

Global Peptide CDMO (Pharmaceutical) Market, by Synthesis Types, 2023-2031 (Value US$ Mn)
• LPPS
• SPPS
• Mixed Phase

Global Peptide CDMO (Pharmaceutical) Market, by Region, 2023-2031 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Peptide CDMO (Pharmaceutical) Market, by Country, 2023-2031 (Value US$ Mn)
• The U.S.
• Canada

Europe Peptide CDMO (Pharmaceutical) Market, by Country, 2023-2031 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Peptide CDMO (Pharmaceutical) Market, by Country, 2023-2031 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Peptide CDMO (Pharmaceutical) Market, by Country, 2023-2031 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America

The Middle East & Africa Peptide CDMO (Pharmaceutical) Market, by Country, 2023-2031 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of the Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global peptide CDMO (pharmaceutical) market
 To receive an industry overview and future trends of the peptide CDMO (pharmaceutical) market
 To analyze the peptide CDMO (pharmaceutical) market drivers and challenges
 To get information on the peptide CDMO (pharmaceutical) market size (Value US$ Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the peptide CDMO (pharmaceutical) market industry

For More Information @ https://www.insightaceanalytic.com/customisation/1202

info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/InsightaceA

InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Peptide CDMO (Pharmaceutical) Market: Navigating Size Success through 9.3 % CAGR Surge by 2031 here

News-ID: 3545403 • Views:

More Releases from InsightAce Analytic Pvt. Ltd.

Organic Feminine Care Market to Benefit from Increasing Government Initiatives and Consumer Awareness on Eco-Friendly and Sustainable Products
Organic Feminine Care Market to Benefit from Increasing Government Initiatives a …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Organic Feminine Care Market Size, Share & Trends Analysis Report By Product Type (Sanitary Pads, Tampons, Menstrual Cups, Liners and Shields, Others), by Nature (Disposable, Reusable), by Age Group (Upto 18 Years, 19-30 Years, 31-40 Years, 41 Years and Above), by Distribution Channel (Supermarkets and hypermarkets, Pharmacy, Online Stores, Others)- Market Outlook And Industry Analysis
Intravenous Immunoglobulin Market Key Players Analysis - Biotest AG, Octapharma AG, LFB Biotechnologies, Grifols SA, CSL Behring, China Biologics Products Inc.
Intravenous Immunoglobulin Market Key Players Analysis - Biotest AG, Octapharma …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Hypogammaglobulinemia, CIDP, Congenital AIDS), By Distribution Channel (hospital pharmacies, speciality pharmacies), Region, Market Outlook And Industry Analysis 2031" The global Intravenous Immunoglobulin market is estimated to reach over USD 21.22 billion by 2031, exhibiting a CAGR of 6.60% during the forecast period. Get Free Access
Exascale Computing Market Key Players Analysis- Hewlett Packard Enterprise Company, International Business Machines Corporation, Intel Corporation, NVIDIA Corporation.
Exascale Computing Market Key Players Analysis- Hewlett Packard Enterprise Compa …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Exascale Computing Market - (By Component (Hardware, Software, Services), By Deployment (On-premises, Cloud-based), By Customer Type (Government & Defense, Healthcare & Biosciences, Financial Services, Research & Academia, Manufacturing & Energy, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global Exascale Computing Market is valued at
Plasma Fractionation Market Robust Expansion is expected to 2031
Plasma Fractionation Market Robust Expansion is expected to 2031
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Plasma Fractionation Market- (By Product (Immune-Globulins(Intravenous Immune-Globulins, Subcutaneous Immune-Globulins, Other Immune-Globulins), Coagulation Factor Concentrates (Factor VIII, Factor IX, Von Willebrand Factor, Prothrombin Complex Concentrate, Fibrinogen Concentrates, Factor XIII, Others), Albumin, Protease Inhibitors, Other Plasma Products), By Application (Neurology, Immunology, Hematology, Critical Care, Pulmonology, Hemato-Oncology, Rheumatology, Others), By End-User (Hospitals & Clinics, Clinical Research Laboratories, Academic Institutes)),

All 5 Releases


More Releases for Peptide

Copper Peptide GHK-Cu Market: Empowering Beauty and Health Innovations with Adva …
The global copper peptide GHK-Cu market is poised for transformative growth as innovative cosmetic and pharmaceutical formulations increasingly incorporate these bioactive peptides to promote skin rejuvenation, wound healing, and overall wellness. Driven by technological advancements, growing consumer awareness of anti-aging solutions, and an expanding portfolio of product applications, the market is set to evolve rapidly in the coming years. This industry provides an in-depth analysis of market information, key growth
Shaping the Cell Penetrating Peptide Market in 2025: Innovative Peptide Drug Dis …
How Big Is the Cell Penetrating Peptide Market Expected to Be, and What Will Its Growth Rate Be? In recent times, the market size for cell penetrating peptides has expanded swiftly. The market is projected to rise from a value of $1.87 billion in 2024 to $2.16 billion in 2025, growing at a compound annual growth rate (CAGR) of 15.6%. The historic period's growth can be credited to an amplified comprehension
Cancer Peptide Drugs Market
Global Peptide Cancer Drug Market Size, Dosage, Drug Price, Sales & Clinical Trials Insight 2030 Report Highlights: • Global Peptide Cancer Drug Market Insight By Region & Indication • Global Peptide Cancer Drug Market Opportunity: > US$ 18 Billion • Approved Peptide Cancer Drugs: > 30 Drugs • Approved Peptide Cancer Drugs Sales Insights, Patent, Dosage and Price Analysis • Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication and Phase • Insight On Peptide Cancer Drugs In Clinical Trials: >
Growing Adoption of Synthetic Peptide Drugs Driving Peptide Therapeutics Market …
Peptide Therapeutics Market size was valued at USD 40.69 billion in 2019 and is poised to grow from USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031). [https://www.skyquestt.com/report/peptide-therapeutics-market] size was valued at USD 43.11 billion in 2023 to USD 68.4 billion by 2031, growing at a CAGR of 5.94% in the forecast period (2024-2031). The increasing prevalence of
Global Adjuvant Peptide Market Size,Share, Research and Forecast,2023-2028| Pept …
The global Adjuvant Peptide market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Adjuvant Peptide market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global
Peptide Modifications For PEGylation
PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established